Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Venlafaxine-Induced Interstitial Lung Disease

  • Oh, Serim (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Cha, Seung-Ick (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Kim, Hyera (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Kim, Minjung (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Choi, Sun Ha (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Seo, Hyewon (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Park, Tae-In (Department of Pathology, Kyungpook National University School of Medicine)
  • Received : 2014.03.20
  • Accepted : 2014.04.29
  • Published : 2014.08.29
Download PDF
⟨ Previous Next ⟩

Abstract

A patient treated with venlafaxine for major depression developed an interstitial lung disease (ILD) with the characteristic clinical, radiological and pathological features of chronic hypersensitivity pneumonitis. A high resolution computed tomography scan demonstrated ground glass opacity, mosaic perfusion with air-trapping and traction bronchiectasis in both lungs. The pathological findings were consistent with a nonspecific interstitial pneumonia pattern. Clinical and radiological improvements were noted after the discontinuation of venlafaxine and the administration of a corticosteroid. This report provides further evidence that the anti-depressant venlafaxine can cause ILD.

Keywords

References

  1. Paparrigopoulos T, Tzavellas E, Karaiskos D, Ilias I, Liappas I. Acute eosinophilic pneumonia after venlafaxine overdose. J Clin Psychopharmacol 2011;31:258-9. https://doi.org/10.1097/JCP.0b013e31820fbecd
  2. Turner RC, Nelson JE, Roberts BT, Gillam DM. Venlafaxine-associated interstitial pneumonitis. Pharmacotherapy 2005;25: 626-9. https://doi.org/10.1592/phco.25.4.626.61029
  3. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55 Suppl A:62-8.
  4. Andrews JM, Ninan PT, Nemeroff CB. Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 1996;4:48-56. https://doi.org/10.1002/(SICI)1522-7162(1996)4:2<48::AID-DEPR2>3.0.CO;2-B
  5. Melien O, Skaali T, Myhr K, Brors O. Venlafaxine and asthma. Nord J Psychiatry 2005;59:538-40. https://doi.org/10.1080/08039480500363595
  6. Tsigkaropoulou E, Hatzilia D, Rizos E, Christodoulou C, Loukides S, Papiris S, et al. Venlafaxine-induced acute eosinophilic pneumonia. Gen Hosp Psychiatry 2011;33:411.e7-9.
  7. Fleisch MC, Blauer F, Gubler JG, Kuhn M, Scherer TA. Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment. Eur Respir J 2000;15:205-8. https://doi.org/10.1183/09031936.00.15120500
  8. Drent M, Singh S, Gorgels AP, Hansell DM, Bekers O, Nicholson AG, et al. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am J Respir Crit Care Med 2003;167:958-61. https://doi.org/10.1164/rccm.200207-739CR
  9. Arias SA, Cohen P, Kwon JS. Clozapine-induced lymphocytic alveolitis. Am J Psychiatry 2011;168:210-1. https://doi.org/10.1176/appi.ajp.2010.10101494
  10. Gonzalez-Rothi RJ, Zander DS, Ros PR. Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. Chest 1995; 107:1763-5. https://doi.org/10.1378/chest.107.6.1763
  11. Borderias Clau L, Marigil Gomez MA, Val Adan P, Marcen Letosa M, Biescas Lopez R, Garrapiz Lopez FJ. Hypersensitivity pneumonitis due to venlafaxine. Arch Bronconeumol 2008;44:571-3.
  12. Patel RA, Sellami D, Gotway MB, Golden JA, Webb WR. Hypersensitivity pneumonitis: patterns on high-resolution CT. J Comput Assist Tomogr 2000;24:965-70. https://doi.org/10.1097/00004728-200011000-00025
  13. Barrera L, Mendoza F, Zuniga J, Estrada A, Zamora AC, Melendro EI, et al. Functional diversity of T-cell subpopulations in subacute and chronic hypersensitivity pneumonitis. Am J Respir Crit Care Med 2008;177:44-55. https://doi.org/10.1164/rccm.200701-093OC
  14. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. https://doi.org/10.1038/clpt.1981.154

Cited by

  1. Venlafaxine : Interstitial lung disease: case report vol.1526, pp.1, 2014, https://doi.org/10.1007/s40278-014-4788-4
  2. Desvenlafaxine-Induced Interstitial Pneumonitis: A Case Report vol.5, pp.1, 2014, https://doi.org/10.1007/s40800-017-0070-z